Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 26.8% – Here’s Why

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 26.8% during trading on Monday . The company traded as low as $0.42 and last traded at $0.45. 86,930,683 shares traded hands during trading, an increase of 196% from the average session volume of 29,385,932 shares. The stock had previously closed at $0.61.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Monday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Down 4.4 %

The stock has a fifty day moving average price of $0.21 and a two-hundred day moving average price of $0.41. The company has a market cap of $72.01 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.